BioNTech is a biotechnology company based in Germany, primarily known for its development of mRNA-based therapeutics and vaccines. Founded in 2008, BioNTech focuses on individualized cancer treatments and infectious diseases using its proprietary mRNA technology platform. The company gained widespread recognition for its collaboration with Pfizer in the development of one of the first COVID-19 vaccines, BNT162b2, which was among the first vaccines to receive emergency authorization during the pandemic. BioNTech’s innovative approach leverages the body’s immune system to fight diseases, making it a significant player in the fields of immunotherapy and vaccine development.
BioNTech is shifting focus from COVID-19 vaccines to developing mRNA-based cancer therapies, aiming for market approval by 2026. The company reported a fourth-quarter earnings of €1.08 per share and revenue…